The role of PET scanning in determining pharmacoselective doses in oncology drug development.
AuthorsPrice, Patricia M
AffiliationAcademic Department of Radiation Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. email@example.com
MetadataShow full item record
AbstractMolecular imaging is the most sensitive and specific method for measuring in vivo molecular pathways in man. Its use in oncology has developed significantly over the last 5-10 years. Molecules can be labelled with positron emitting isotopes and the emitted radiation is detected using sensitive positron emission tomography (PET) cameras. It is now possible to measure in vivo and normal tissue pharmacokinetics of anti-cancer drugs and investigate their mechanism of action. Radiolabelling of tracers can be used to measure specific pharmacodynamic endpoints and target identification. Increasing evidence shows how these technologies, when added to early drug development, can rapidly reduce the time for entry into man and early identification of mechanisms of action. With the move towards more segmented markets and identification of specific subgroups, PET's use for noninvasive biomarkers will become in- creasingly important. However, much international effort between academia and industry is required with prioritisation of development of this technology.
CitationThe role of PET scanning in determining pharmacoselective doses in oncology drug development. 2007 (59):185-93 Ernst Schering Res. Found. Workshop
JournalErnst Schering Research Foundation Workshop
- Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective.
- Authors: Murphy PS, Bergström M
- Issue date: 2009
- Clinical molecular imaging with positron emission tomography.
- Authors: Saleem A, Charnley N, Price P
- Issue date: 2006 Aug
- The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.
- Authors: Roselt P, Meikle S, Kassiou M
- Issue date: 2004 Jan-Mar
- The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
- Authors: Maynard J, Emmas SA, Ble FX, Barjat H, Lawrie E, Hancox U, Polanska UM, Pritchard A, Hudson K
- Issue date: 2017
- Positron emission tomography imaging as a key enabling technology in drug development.
- Authors: McCarthy TJ
- Issue date: 2007